Cochrane · systematic review · CD009498
Transarterial (chemo)embolisation versus no intervention or placebo for liver metastases
Swierz, MJ, Storman, D, Riemsma, RP, et al. · Cochrane Database of Systematic Reviews · 2020 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
21
current version
GRADE rated
12
No studies
9
Included studies
NR
No studies 9 · 42.9%Ungraded 0 · 0%Very low 12 · 57.1%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Current version onlyTransarterial embolisation and transarterial chemoembolisation compared with no intervention for liver metastases
Population: people with liver metastases
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mortality at 44 months from trial entry Number of participants Transarterial embolisation and transarterial chemoembolisation vs no intervention | RR 0.88 [0.74, 1.06] | 1 study · 61 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Survival time Median (range) survival time after trial entry Survival time Median (range) survival time from diagnosis Transarterial embolisation and transarterial chemoembolisation vs no intervention | no estimate extracted | 1 study · 61 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Failure to clear liver metastases or recurrence of liver metastases Transarterial embolisation and transarterial chemoembolisation vs no intervention | no estimate extracted | 1 study · 61 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Time to progression of liver metastases Transarterial embolisation and transarterial chemoembolisation vs no intervention | no estimate extracted | NR | No studies |
Tumour response measures Transarterial embolisation and transarterial chemoembolisation vs no intervention | no estimate extracted | NR | No studies |
Health‐related quality of life Transarterial embolisation and transarterial chemoembolisation vs no intervention | no estimate extracted | NR | No studies |
Adverse events and complications Transarterial embolisation and transarterial chemoembolisation vs no intervention | no estimate extracted | 1 study · 61 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Transarterial embolisation compared with no intervention for liver metastases
Population: people with liver metastases
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mortality at 44 months from trial entry Number of participants Transarterial embolisation vs no intervention | RR 0.91 [0.75, 1.1] | 1 study · 42 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Survival time Median (range) survival time after trial entry Survival time Median (range) survival time from diagnosis Transarterial embolisation vs no intervention | no estimate extracted | 1 study · 42 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Failure to clear liver metastases or recurrence of liver metastases Transarterial embolisation vs no intervention | no estimate extracted | 1 study · 42 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Time to progression of liver metastases Transarterial embolisation vs no intervention | no estimate extracted | NR | No studies |
Tumour response measures Transarterial embolisation vs no intervention | no estimate extracted | NR | No studies |
Health‐related quality of life Transarterial embolisation vs no intervention | no estimate extracted | NR | No studies |
Adverse events and complications Transarterial embolisation vs no intervention | no estimate extracted | 1 study · 42 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Transarterial chemoembolisation compared with no intervention for liver metastases
Population: people with liver metastases
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mortality at 44 months from trial entry Number of participants Transarterial chemoembolisation vs no intervention | RR 0.83 [0.65, 1.07] | 1 study · 39 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Survival time Median (range) survival time after trial entry Survival time Median (range) survival time from diagnosis Transarterial chemoembolisation vs no intervention | no estimate extracted | 1 study · 39 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Failure to clear liver metastases or recurrence of liver metastases Transarterial chemoembolisation vs no intervention | no estimate extracted | 1 study · 39 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Time to progression of liver metastases Transarterial chemoembolisation vs no intervention | no estimate extracted | NR | No studies |
Tumour response measures Transarterial chemoembolisation vs no intervention | no estimate extracted | NR | No studies |
Health‐related quality of life Transarterial chemoembolisation vs no intervention | no estimate extracted | NR | No studies |
Adverse events and complications Transarterial chemoembolisation vs no intervention | no estimate extracted | 1 study · 39 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Transarterial (chemo)embolisation compared to no intervention or placebo intervention for liver metastases
Population: liver metastases.
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mortality Participsants alive at last Transarterial (chemo)embolisation vs no intervention or placebo intervention | RR 0.91 [0.75, 1.1] | 1 study · 42 participants | Very low Downgraded: risk of bias |
Time to mortality Median survival after trial entry. Scale from: 1 to 44. Transarterial (chemo)embolisation vs no intervention or placebo intervention | no estimate extracted | 1 study · 42 participants | Very low Downgraded: risk of bias |
Extrahepatic disease Number of patients developing evidence of extrahepatic disease. Transarterial (chemo)embolisation vs no intervention or placebo intervention | RR 1.64 [0.6, 4.07] | 1 study · 42 participants | Very low Downgraded: risk of bias |
Transarterial (chemo)embolisation compared to no intervention or placebo intervention for liver metastases
Population: liver metastases.
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mortality Participsants alive at last Transarterial (chemo)embolisation vs no intervention or placebo intervention | RR 0.91 [0.75, 1.1] | 1 study · 42 participants | Very low Downgraded: risk of bias |
Time to mortality Median survival after trial entry. Scale from: 1 to 44. Transarterial (chemo)embolisation vs no intervention or placebo intervention | no estimate extracted | 1 study · 42 participants | Very low Downgraded: risk of bias |
Extrahepatic disease Number of patients developing evidence of extrahepatic disease. Transarterial (chemo)embolisation vs no intervention or placebo intervention | RR 1.64 [0.6, 4.07] | 1 study · 42 participants | Very low Downgraded: risk of bias |